New Pharmacological Treatment for Obstructive Sleep Apnea

Completed · Phase 1

Conditions studied: Obstructive Sleep Apnea

In brief

This study will determine if mirtazapine, a unique antidepressant that does not disturb sleep, will improve obstructive sleep apnea (OSA). The design is randomized, crossover, double blind, and placebo controlled. On two consecutive nights of one week, the patients receive either 30 mg mirtazapine or placebo at bedtime. The following week, the alternative medication is administered. The patients have known mild to moderate sleep apnea. The endpoints of the study are the apnea + hypopnea index (AHI), sleep quality, and the degree of arterial oxygen desaturation.

Key facts

Study ID

NCT00108498

Run by

US Department of Veterans Affairs

Starts

2003-10-01

Expected to finish

2007-03-01

Last updated by the study team

2009-01-21

Who can join

Age: 20 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Known OSA mild to moderate

You may not qualify if…

• On antidepressant or antipsychotic medications

Where it is running

• Malcom Randall VAMC — Gainesville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.